Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 22:10:572380.
doi: 10.3389/fonc.2020.572380. eCollection 2020.

Overall Survival in Heart Disease-Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study

Mohammed Safi  1 , Ravindran Kanesvaran  2 , Mohammed Alradhi  3 , Abdullah Al-Danakh  1 , Feng Ping  1 , Najeeb Al-Sabai  4 , Xiu Shan  1 , Jiwei Liu  1
Affiliations

Overall Survival in Heart Disease-Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study

Mohammed Safi et al. Front Oncol. .

Abstract

The cardiotoxicity during immunotherapy administration leads to mortality by more than 42% and heart disease-related mortality among immunotherapy-linked cancers is still considered to be underestimated. In this study, the advanced stage of non-small cell lung cancer (NSCLC) with heart disease-related death was selected in accordance with immunotherapy approval time. NSCLC was searched on the Surveillance, Epidemiology, and End Results (SEER) program. Results show that 538 advanced NSCLC cases, those dominated by men and elderly people aged more than 70 years, had a high percentage of heart disease-related death in both eras. The difference between contemporary groups was fairly nonsignificant (P = > 0.05). The overall survival (OS) of all-cause mortality difference showed improved survival in the immunotherapy group (P = 0.0001). In the study of heart disease-related death survival with adjusted data, the NSCLC patients show significant lower survival in the immunotherapy era compared with the nonimmunotherapy era (P = 0.003; hazard ratio [HR] = 1.31; 95% CI = 1.099-1.57). In the multivariate analysis of NSCLC-related immunotherapy, histology revealed that the non-squamous cell type had an independent risk for lower OS than the squamous cell type (P = 0.04; HR= 0.74; CI = 0, 55- 0.99). The results demonstrate the survival benefits for NSCLC in immunotherapy; however, in heart disease-related death, immunotherapy in patients with NSCLC shows decreased OS. This study highlights that NSCLC patients should be highly monitored during immunotherapy administration, and further assessment is needed.

Keywords: SEER database; cardiotoxicity; heart diseases; immunotherapy; non-small cell lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagram of exclusion and inclusion criteria.
Figure 2
Figure 2
(A) KM NSCLC curve comparing OS of all-cause mortality (P= 0.0001). (B) OS difference in patients who died from heart diseases with negative OS in the NSCLC immunotherapy era (P = 0.0001).
Figure 3
Figure 3
KM curve comparing OS. Factors difference between NSCLC nonimmunotherapy versus immunotherapy era.
Figure 4
Figure 4
(A) KM curve showing OS difference among factors in the NSCLC immunotherapy group of hear related- death patients. (B) Cox multivariate analysis difference survival of heart related death patients between NSCLC nonimmunotherapy group and immunotherapy group.
See this image and copyright information in PMC

Comment in

References

    1. Eduati F, Lapuente-Santana Ó. Towards systems biomarkers of response to immune checkpoint blockers. Front Oncol (2020) 10:1027. 10.3389/fonc.2020.01027 - DOI - PMC - PubMed
    1. Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B., Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol (2018) 19(12):1579–89. 10.1016/S1470-2045(18)30608-9 - DOI - PMC - PubMed
    1. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol (2020) 17(8):1–29. 10.1038/s41569-020-0348-1 - DOI - PMC - PubMed
    1. Dores GM, Bryant-Genevier M, Perez-Vilar S. Adverse events associated with the use of sipuleucel-T reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017. JAMA Netw Open (2019) 2(8):e199249–e199249. 10.1001/jamanetworkopen.2019.9249 - DOI - PMC - PubMed
    1. Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA: Cancer J Clin (2020) 70(2):86–104. 10.3322/caac.21596 - DOI - PubMed

LinkOut - more resources